Type 4B hereditary hemochromatosis associated with a novel mutation in the SLC40A1 gene
A case report and a review of the literature

Wei Zhang, MD, Tingxia Lv, MD, Jian Huang, PhD, Xiaojuan Ou, MD, and Xiaojuan Ou, MD

Abstract
Rationale: Hereditary hemochromatosis can be divided into HFE- and non-HFE-related based on genetic mutations in different genes. HFE-related hemochromatosis is the most common inherited genetic disease in European populations but rare in Asia-Pacific region. Recently, non-HFE-related hemochromatosis has been reported in patients from the Asian countries.

Patient concerns: We report the case of a 48-year-old Chinese Han woman who presented with abnormal liver function, diabetes mellitus, hyperferritinemia, and high transferrin saturation, with severe iron overload in parenchymal cells, Kupffer cells, and perportal fibrosis on liver biopsy. No secondary factor for iron overload was identified.

Diagnoses: Sanger sequencing was conducted for the screening of mutation in the hereditary hemochromatosis related genes. The functional effect of a splicing mutation, SLC40A1 IVS 3+10 del gtt, was assessed by reverse-polymerase chain reaction analysis for SLC40A1 mRNA level, and by immunohistochemistry analysis of liver biopsy for ferroportin expression and cellular localization.

Outcomes: A novel splicing mutation IVS 3+10 del gtt was identified in the SLC40A1 gene. Functional analysis showed that IVS 3+10 del gtt in the SLC40A1 gene lead to a substantial reduction in the basal levels of SLC40A1 mRNA and increased membrane localization of ferroportin. Finally, the patient was diagnosed as ferroportin disease (type 4B hemochromatosis).

Lessons: The present study is the first report to identify a classical splicing mutation in the SLC40A1 gene in type 4B hereditary hemochromatosis, and provide further evidence of the prevalence of type 4 hereditary hemochromatosis in Asian countries.

Abbreviations: BSA = albumin from bovine serum, GRE = gradient-echo, HAMP = hepcidin antimicrobial peptide, HFE = hemochromatosis, HH = hereditary hemochromatosis, HJV = hemojuvelin, IHC = immunohistochemistry, MRI = magnetic resonance imaging, PBS = phosphate buffer saline, RT-PCR = reverse transcriptase–polymerase chain reaction, SLC40A1 = solute carrier family 40 member 1.

Keywords: case report, hemochromatosis, iron overload, liver, SLC40A1, splicing mutation

1. Introduction
Hereditary hemochromatosis (HH) is a genetic disorder characterized by iron deposition and tissue injury in multiple organs.[1] The genetic bases for hemochromatosis can be divided principally into hemochromatosis (HFE) gene mutations and non-HFE mutations.[2] The principal HFE gene defect was first identified in 1996, and is a G-to-A missense mutation, leading to the substitution of tyrosine for cysteine at amino acid position 282 of the protein product (C282Y); the other 2 relatively common HFE mutations were H63D and S65C.[3] HFE-related HH is the most common inherited genetic disease in European populations.[1] Mutations in all the currently known genes implicated in non-HFE HH, such as hemojuvelin (HJV), hepcidin antimicrobial peptide (HAMP), transferrin receptor 2 (TFR2), and solute carrier family 40 member 1 (SLC40A1), have been reported in patients from Asia-Pacific region.[1] Further, a meta-analysis found that 80.6% (2260/2802) of HH patients are homozygous for the C282Y mutation of HFE,[4] yet this mutation is not found in Chinese patients.[4] Here, we report a novel SLC40A1 mutation, IVS 3+10 del gtt, in a Chinese Han woman with severe iron overload disease.

2. Clinical report
2.1. Patient identification
A 48-year-old female patient who had been suffering from asthenia and intermittent vomiting for 9 months was admitted to our hospital. She had no other gastrointestinal symptoms, but had been diagnosed with diabetes mellitus for 2 years. She had never taken supplemental iron and did not consume alcohol. Physical examination was normal. Laboratory biochemistry results were as follows: alanine aminotransferase (ALT) 62 U/L (normal: 7–40 U/L); aspartate aminotransferase (AST) 68 U/L (normal: 13–35 U/L); alkaline phosphatase (ALP), 113 U/L.
(normal: 35–100 U/L); γ-glutamyltransferase (GGT), 49 U/L (normal: 7–45 U/L); and total and conjugated bilirubin (TB/DB), 7.35 and 0.86 μmol/L, respectively. Serum markers for viral hepatitis were negative. Antimitochondrial antibody (M2) and immunoglobulin M were normal. Ceruloplasmin was 0.20 g/L (normal: 0.20–0.60 g/L). Iron studies showed: iron 34.34 μmol/L, transferrin saturation 100%, and ferritin 7078 μg/L. Magnetic resonance imaging (MRI) of the abdomen showed a significant iron overload in the liver and spleen (Fig. 1). A liver biopsy was performed for diagnostic purposes and staging of her liver disease. The specimen obtained was prepared with hematoxylin/eosin and Berlin blue staining. Histological examination of the specimen showed grade 3 iron stores (using the Scheuer scoring system), predominantly in parenchymal cells, but with significant iron deposits in Kupffer cells and portal tract macrophages (Fig. 2). In addition, periportal fibrosis was observed, but no cirrhosis was evident.

2.2. Detection of genetic mutations
Informed consent was obtained before taking a blood sample for gene analysis of HFE (C282Y and H63D), HJV, HAMP, TFR2,
and SLC40A1. Efforts were made to contact and obtain blood samples from family members. However, owing to circumstances beyond our control, none could be contacted.

Genomic DNA was extracted from peripheral blood leukocytes using the Genomic DNA Puriﬁcation Kit (Qiagen, Valencia, CA). Whole exons were ampliﬁed from the HFE, HJV, HAMP, TFR2, and SLC40A1 genes, and their associated boundary regions by polymerase chain reaction (PCR) using the primers described in our previous study. Ampliﬁcation was performed with an initial denaturation of 1 cycle of 95°C for 5 minutes, followed by 38 cycles of 95°C for 1 minute, annealing at 50 to 60°C for 70 seconds, and 72°C for 5 minutes. PCR products were sequenced using the ABI3730 automated DNA sequencer. The cDNA reference sequence was submitted to GenBank (https://www.ncbi.nlm.nih.gov/genbank/) and analyzed by ExPASy (http://web.expasy.org/translate/). The results showed that the patient had a splicing mutation, IVS3+10 del gtt, in the SLC40A1 gene (Fig. 3). No mutations were identiﬁed in the other 4 genes.

2.3. Reverse transcriptase–PCR (RT-PCR) analysis of SLC40A1 gene transcripts

Total RNA was isolated from formalin-ﬁxed parafﬁn-embedded tissue of the patient using the RNasy FFPE Kit (Qiagen, Valencia, CA) according to the manufactory’s protocol, and the reverse-transcript was conducted using the High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems, Foster city, CA). cDNA of BEL7402 cell line and normal liver tissue were provided by Dr Anjian Xu (Experimental Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China) and used as control for RT-PCR analysis. RT-PCR covering the coding sequence of exons 3 to 4 of SLC40A1 was performed with the primers as follows: 5’-TTGCGGTGTCTGTGTTTCTG-3’ (in exon 3) and 5’-AGGTCCTGGGCCACTTTAAGT-3’ (in exon 4) for SLC40A1, and 5’-GAGTCAACCGGATTTGCTGT-3’ and 5’-GAGTCAACCGGATTTTGGTCGT-3’ for GAPDH as control. The reactions were performed in an ABI GeneAmp PCR System 9700 (Applied Biosystems, Foster City, CA) with the following program: denaturation for 30seconds at 94°C, annealing for 30 seconds at 60°C, and elongation for 30 seconds at 72°C for 35 cycles; the ﬁnal extension at 72°C for 7 minutes. Equal volumes of each PCR sample were subjected to electrophoresis in a 1.5% agarose gel, and the PCR product of SLC40A1 was conducted sequencing with the same primer for PCR.

The results showed a substantial reduction in the basal levels of SLC40A1 mRNA in the case with SLC40A1 IVS3+10 del gtt mutation compared with that of the controls (Fig. 4A), suggesting...
than 30 case reports of ferroportin disease had been reported,[7] which is a classical splicing mutation. To our knowledge, more visualization of antigen formed using antibodies against ferroportin (NBP1 antibody (MP-7401, Vector) was used at 37°C serum for at least 1 hour at room temperature to block nonspecific staining. Immunohistochemical staining was performed using antibodies against ferroportin (NBP1–21502, Novus) at a dilution of 1:800 at 4°C overnight. Secondary antibody (MP-7401, Vector) was used at 37°C for 1 hour, and visualization of antigen–antibody reactions were achieved with 3,3'-diaminobenzidine (DAB, Vector kit SK-4100).

Increased staining of ferroportin was shown in the cell membranes in the liver tissue with the SLC40A1 IVS3+10 del gtt mutation compared with that of the normal liver tissue, suggesting the increased membrane localization of ferroportin (Fig. 4B).

### 3. Discussion

Currently, 4 major categories of hereditary hemochromatosis have been established, including HFE-related or type 1 hemochromatosis (which is common in Caucasians), type 2 (A and B) hemochromatosis with mutation in HJV or HAMP, type 3 hemochromatosis with mutation in TFR2, and type 4 hemochromatosis (ferroportin disease) with mutation in SLC40A1.[6] In this report, we describe the clinical and laboratory features of a case diagnosed with HH, who has a previously unrecognized ferroportin mutation, specifically, SLC40A1: IVS3+10 del gtt, which is a classical splicing mutation. To our knowledge, more than 30 case reports of ferroportin disease had been reported,[7] but all the mutations reported in those reports were missense mutation without functional analysis, so the biological consequence of the identified mutations remains to be explored. However, the case in the present study is the first report to identify a classical splicing mutation in the SLC40A1 gene in type 4B hemochromatosis.

Ferroportin disease (type 4 HH) is due to pathogenic mutations in the SLC40A1 gene, which encodes a main iron export protein called “ferroportin1/IREG1/MTP1.”[8] By altering the physicochemical properties of this protein, these mutations cause iron overload via an intracellular retention mechanism.[9] According to the different phenotypes, ferroportin disease is divided into 2 types: type 4A (classical ferroportin disease) and type 4B (nonclassical ferroportin disease).[9] The phenotypic features of type 4A and type 4B HH are summarized in Table 1.[7–9] It is assumed that the phenotypes of patients with SLC40A1 mutations vary depending on the mutation.[10] Mutations leading to ferroportin that is either not present normally at the cell surface or has defective iron export activity (loss of function) are associated with iron deposition in Kupffer cells and low transferrin saturation,[10] and define type 4A. Those mutated ferroportin that cannot be internalized after hepcidin binding (gain of function) are associated with iron deposition in hepatocytes and elevated transferrin saturation,[10] and define type 4B. A systemic meta-analysis of 176 individuals reported that SLC40A1 mutations, namely, V162del, D157N, D181V, G80V, Q182H, and R489K, may impair ferroportin’s iron export function, and are common mutations for type 4A HH. Conversely, the mutations Y64N, V72F, and Y501C confer hepcidin resistance and are common mutations for type 4B HH.[7]

Chen et al.[11] reported the first type 4B HH case in the Chinese Han population. They found a novel heterozygous mutation (p. Cys326Phe) in the SLC40A1 gene, which results in hepcidin resistance, although this finding needs in vitro confirmation. Our case here is the first case report of type 4B HH associated with the identified IVS3+10 del gtt mutation in the SLC40A1 gene. The typical splicing mutation, IVS3+10 del gtt, is located in intron 3 of the SLC40A1 gene, 9 bases away from the end base of exon 3. Subsequently, this mutation may lead to a splicing error that results in incorrect assembly of ferroportin protein and a consequent change in function. In a recent study, a single heterozygous MSXI IVS1+5GA mutation was identified in a case affected with tooth agenesis. Although RNA sequencing showed correct joining of exon 1 and exon 2 sequences, a substantial reduction of the levels of MSXI mRNA was observed, indicating that the novel variant may reduce efficiency of the splicing of pre-mRNA, and thus lead to the decrease of mRNA level.[12] Previous studies have demonstrated the reduced efficiency of pre-mRNA splicing in other genes containing the

### Table 1

Comparison of phenotypic profiles between type 4A and type 4B hereditary hemochromatosis.

|                          | Serum iron and transferrin saturation | Iron deposition on liver biopsy | MRI | Response to phlebotomy | Prognosis                              |
|--------------------------|--------------------------------------|----------------------------------|-----|------------------------|----------------------------------------|
| **Type 4A**              | Normal or mild elevated              | Predominant in the Kupffer cells | Iron overload prevails in the spleen (“black spleen and grey liver”) | Low tolerance with risk of anemia       | Relative benign                        |
| **Type 4B**              | Elevated markedly                    | Predominant in the hepatocytes, lack of iron in Kupffer cells if liver biopsy performed at early stages | Diffuse hepatic iron excess without splenic iron (“black liver and white spleen”) | Tolerance, strong efficient            | Chronic iron overload progressively damages the hepatocytes leading to hepatomegaly, progressive fibrosis and cirrhosis with the risk of hepatocellular carcinoma |

MRI = magnetic resonance imaging.
intronic mutation downstream of the consensus donor site. In the above study, primer sets targeting exon 1 and 2 sequences were used to assess cDNA replicates. Compared with unaffected individuals, significantly reduced MSX1 mRNA expression was observed in the proband. Similarly, in the present study, primer sets targeting exon 3 and 4 sequences were used to assess cDNA replicates, and the results showed significantly reduced SLC40A1 mRNA expression compared with that of the controls, suggesting the SLC40A1 IVS3+10 del gtt may lead to abnormal splicing of mRNA.

In addition, the IHC analysis of ferroportin showed increased staining of ferroportin in the cell membranes in the liver tissue with the SLC40A1 IVS3+10 del gtt, compared with that of the normal liver tissue. The increased membrane localization of ferroportin, one of the characteristics of type 4B HH, may result from the abnormal SLC40A1 transcripts, of which the encoded mutated ferroportin cannot be internalized after hepcidin binding.

This patient presented with abnormal liver function, diabetes mellitus, hyperferritinemia, and high transferrin saturation, with compound iron overload in parenchymal cells and Kupffer cells, periportal fibrosis on liver biopsy, and was heterozygous for a novel mutation in the SLC40A1 gene. Therefore, the final diagnosis of the patient was type 4B (nonclassical) hereditary hemochromatosis.

4. Conclusions

In conclusion, we have identified the IVS3+10 del gtt mutation of ferroportin 1 in a Chinese individual. This mutation is associated with high transferrin saturation, parenchymal iron loading, and advanced fibrosis. This case is the first report to identify a classical splicing mutation in the SLC40A1 gene and emphasizes the importance of non-HFE mutations in hereditary hemochromatosis in Asian countries.

Acknowledgments

We thank Professor Tai-Ling Wang and Doctor Chen Shao (Department of Pathology, Beijing China-Japan Friendship Hospital, Beijing, China) for reviewing liver biopsies and taking pictures.

References

[1] Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet 2016;388:706–16.
[2] McDonald CJ, Wallace DF, Crawford DHG, et al. Iron storage disease in Asia-Pacific populations: the importance of non-HFE mutations. J Gastroen Hepatol 2013;28:1087–94.
[3] European Association For The Study Of The Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010;53:3–22.
[4] Tsui WM, Lam PW, Lee KC, et al. The C282Y mutation of the HFE gene is not found in Chinese haemochromatotic patients: multicentre retrospective study. Hong Kong Med J 2000;6:153–8.
[5] Lv T, Zhang W, Li X, et al. Characteristics of gene mutation in Chinese patients with hereditary hemochromatosis (Chinese). J Clin Hepatol 2016;8:1288–93.
[6] Brissot P, Troedec M, Bardou-Jacquet E, et al. Current approach to hemochromatosis. Blood Rev 2008;22:195–210.
[7] Mayr R, Janecke AR, Schranz M, et al. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J Hepatol 2010;53:941–9.
[8] Pietrangelo A. The ferroportin disease. Blood Cells Mol Dts 2004;32:131–8.
[9] Brissot P, Loral O. Iron metabolism and related genetic diseases: a cleared land, keeping mysteries. J Hepatol 2016;64:505–15.
[10] Lee PL, Gelbart T, West C, et al. SLC40A1c.1402G>A results in aberrant splicing, ferroportin truncation after glycine 330, and an autosomal dominant hemochromatosis phenotype. Acta Haematol-Basel 2007;118:237–41.
[11] Chen SR, Yang LQ, Chong YT, et al. Novel gain of function mutation in the SLC40A1 gene associated with hereditary haemochromatosis type 4. Intern Med J 2015;45:672–6.
[12] Xue J, Gao Q, Huang Y, et al. A novel MSX1 intronic mutation associated with autosomal dominant non-syndromic oligodontia in a large Chinese family pedigree. Clin Chim Acta 2016;461:135–40.
[13] Zampieri S, Buratti E, Dominissini S, et al. Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients’ phenotypes. Eur J Hum Genet 2011;19:422–31.